JP2001509135A5 - - Google Patents

Download PDF

Info

Publication number
JP2001509135A5
JP2001509135A5 JP1998517803A JP51780398A JP2001509135A5 JP 2001509135 A5 JP2001509135 A5 JP 2001509135A5 JP 1998517803 A JP1998517803 A JP 1998517803A JP 51780398 A JP51780398 A JP 51780398A JP 2001509135 A5 JP2001509135 A5 JP 2001509135A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998517803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509135A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/018718 external-priority patent/WO1998016238A2/en
Publication of JP2001509135A publication Critical patent/JP2001509135A/ja
Publication of JP2001509135A5 publication Critical patent/JP2001509135A5/ja
Ceased legal-status Critical Current

Links

JP51780398A 1996-10-11 1997-10-10 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法 Ceased JP2001509135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2854896P 1996-10-11 1996-10-11
US60/028,548 1996-10-11
PCT/US1997/018718 WO1998016238A2 (en) 1996-10-11 1997-10-10 Cancer immunotherapy using tumor cells combined with mixed lymphocytes

Publications (2)

Publication Number Publication Date
JP2001509135A JP2001509135A (ja) 2001-07-10
JP2001509135A5 true JP2001509135A5 (cg-RX-API-DMAC10.html) 2005-06-16

Family

ID=21844058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51780398A Ceased JP2001509135A (ja) 1996-10-11 1997-10-10 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法

Country Status (13)

Country Link
US (1) US6207147B1 (cg-RX-API-DMAC10.html)
EP (1) EP0930887B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001509135A (cg-RX-API-DMAC10.html)
KR (1) KR20000049096A (cg-RX-API-DMAC10.html)
CN (1) CN1237909A (cg-RX-API-DMAC10.html)
AR (1) AR004445A1 (cg-RX-API-DMAC10.html)
AT (1) ATE229810T1 (cg-RX-API-DMAC10.html)
AU (1) AU743855B2 (cg-RX-API-DMAC10.html)
BR (1) BR9712988A (cg-RX-API-DMAC10.html)
CA (1) CA2267157C (cg-RX-API-DMAC10.html)
DE (1) DE69718029T2 (cg-RX-API-DMAC10.html)
NO (1) NO991691L (cg-RX-API-DMAC10.html)
WO (1) WO1998016238A2 (cg-RX-API-DMAC10.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
WO1998048000A2 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of California A cell strain with activated anti-cancer cytotoxic activity
WO1999018981A1 (en) * 1997-10-10 1999-04-22 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
WO1999018980A1 (en) 1997-10-10 1999-04-22 Meyer Pharmaceuticals, Llc Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
AU9794698A (en) * 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
JP4389039B2 (ja) * 1998-04-09 2009-12-24 株式会社リンフォテック アロジェニックな活性化cd4陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
DE60040213D1 (de) * 1999-02-09 2008-10-23 Riken Wako Tumorimpfstoff
CA2404388C (en) 2000-04-01 2010-06-15 Onyvax Limited New prostate cell lines
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
WO2002091997A2 (en) * 2001-05-11 2002-11-21 Pro-Virus, Inc. Oncolytic virus therapy
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
ATE386129T1 (de) * 2001-11-27 2008-03-15 Nexyte Ab Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
KR20020060643A (ko) * 2002-06-04 2002-07-18 김진경 타인의 면역시스템을 이용하는 암의 치료 방법
US7695713B2 (en) * 2002-08-08 2010-04-13 Baylor College Of Medicine Isolation and identification of T cells
US7571817B2 (en) * 2002-11-06 2009-08-11 Varco I/P, Inc. Automatic separator or shaker with electromagnetic vibrator apparatus
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
DE602004011061T2 (de) 2003-06-11 2008-11-06 The University Of Chicago, Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
AU2004280616A1 (en) * 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050112684A1 (en) * 2003-11-21 2005-05-26 Eric Holzle Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners
ATE552851T1 (de) 2004-02-03 2012-04-15 Univ Michigan Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
JP5129149B2 (ja) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
WO2007133250A2 (en) 2005-10-31 2007-11-22 Austin Gurney Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
AU2007247869B2 (en) * 2006-05-05 2013-11-21 Opexa Therapeutics T-cell vaccine
WO2008019290A2 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US8691568B2 (en) * 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US8455188B2 (en) * 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
EP2650018A3 (en) 2007-05-14 2014-09-03 The University of Chicago Antibody-LIGHT fusion products for cancer therapeutics
CN101855549A (zh) * 2007-09-12 2010-10-06 耶达研究及发展有限公司 在免疫豁免部位内治疗肿瘤的方法
US8114276B2 (en) 2007-10-24 2012-02-14 Baxter International Inc. Personal hemodialysis system
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US9101726B2 (en) * 2008-04-07 2015-08-11 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
CN102753193A (zh) * 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
HRP20170463T1 (hr) 2008-11-11 2017-05-19 The Regents Of The University Of Michigan Pripravci i postupci protiv cxcr1
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CA2796379A1 (en) * 2009-10-27 2011-05-05 Immunicum Ab Method for proliferation of antigen-specific t cells
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
US20110237461A1 (en) * 2010-03-17 2011-09-29 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Reiメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
EP2704741B1 (en) * 2011-05-03 2017-08-23 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
RU2670745C9 (ru) * 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
EP2790730B1 (en) 2011-12-15 2019-01-23 The University of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015048305A1 (en) * 2013-09-27 2015-04-02 Vaccinogen, Inc. Autologous tumor vaccines and methods
SG11201703406YA (en) 2014-11-05 2017-05-30 Sloan Kettering Inst Cancer Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2016145292A1 (en) * 2015-03-12 2016-09-15 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting cancer
EP3756676B1 (en) * 2015-06-26 2023-01-11 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
EP3328399B1 (en) 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
WO2017087784A1 (en) 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
AU2017346885B2 (en) 2016-10-18 2021-10-21 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
WO2018138682A1 (en) 2017-01-26 2018-08-02 Immune Therapeutics Methods and compositions useful for treating cancer
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス,インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
FR3082730B1 (fr) * 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
JP2639835B2 (ja) * 1988-11-30 1997-08-13 有限会社ジオリサーチ 免疫記憶細胞懸濁液の調製方法
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
WO1994020120A1 (en) 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
EP0734440A1 (en) 1993-12-14 1996-10-02 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
ES2530769T3 (es) * 1994-06-14 2015-03-05 Univ Leland Stanford Junior Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
AU696572B2 (en) * 1995-03-17 1998-09-10 Regents Of The University Of California, The Method for treating tumors
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000515496A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2001503427A5 (cg-RX-API-DMAC10.html)
JP2000505324A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2001509135A5 (cg-RX-API-DMAC10.html)
JP2000516683A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000500026A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2001503324A5 (cg-RX-API-DMAC10.html)
JP2001511826A5 (cg-RX-API-DMAC10.html)
JP2000510181A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000516286A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000516366A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)